MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird

MiNK Therapeutics (NASDAQ:INKT) had its price objective lowered by Robert W. Baird from $8.00 to $4.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of MiNK Therapeutics in a report on Wednesday, October 9th.

MiNK Therapeutics Trading Up 0.5 %

Shares of INKT stock opened at $0.75 on Friday. The stock has a market capitalization of $29.81 million, a price-to-earnings ratio of -1.93 and a beta of 0.05. MiNK Therapeutics has a 12-month low of $0.57 and a 12-month high of $1.90. The stock’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.85.

Institutional Trading of MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.